Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic highrisk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Evolve CLL/SLL study (SWOG S1925; NCT#04269902) Meeting Abstract
| Authors: | Stephens, D. M.; Moseley, A.; Hill, B. T.; Pagel, J. M.; Shadman, M.; Fisch, M.; Danilov, A. V.; Ng, D.; Mato, A. R.; Brander, D. M.; Othus, M.; Coutre, S.; O'Brien, S. M.; Erba, H. P. |
| Abstract Title: | Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic highrisk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Evolve CLL/SLL study (SWOG S1925; NCT#04269902) |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413902143 |
| DOI: | 10.1182/blood-2021-144780 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2630 -- Hybrid meeting, also took place online -- Source: Wos |
